Navigation Links
Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
Date:10/8/2007

n safety study is a multi-center, double blind trial that will enroll approximately 200 patients who have participated in the 301 or 303 phase 3 trials. Study participants will continue to receive the same study medication they received in the other trials which was either HZT-501 (ibuprofen 800 mg/famotidine 26.6 mg) or ibuprofen 800 mg. Study participants will receive medication for up to 28 weeks.

About the Pain Market

HZT-501 targets the widespread medication void in the mild-to-moderate pain market left by COX-2 inhibitors which have either been taken off the market or are being prescribed less frequently due to elevated cardiovascular risk. From 2004 to 2006, the U.S. NSAID market grew over 20 percent to 73 million prescriptions. Over 26 million ibuprofen prescriptions are now written annually in the United States alone.

However, while commonly prescribed to treat pain, NSAIDs have been linked to serious gastrointestinal (GI) side effects in up to 25 percent of all chronic arthritis patients. NSAID-induced GI toxicity causes an estimated 16,000 deaths and more than 100,000 hospitalizations annually in the United States. Despite this, studies have shown that as low as 30% of high-risk patients are commonly co-prescribed a gastro-protective agent in combination with their NSAID. In addition, patient adherence to a regimen of separate GI protective and pain medications has also been shown to be poor.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a novel portfolio of therapies through innovative combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, entered Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combinat
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Roche,s Bloodhound technology is ... segment in hematology testing, according to Kalorama Information.  ... unveiling of its Bloodhound digital cell imaging technology ... 511 hematology analyzer – is notable as ... by current leader CellaVision, but also compete more ...
(Date:7/2/2015)... DALLAS , July 2, 2015 ... Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial ... Trends & Global Forecast to 2020", published by MarketsandMarkets, the ... and is projected to reach $6.20 Billion by 2020, at ... Browse 8 4 market ...
(Date:7/2/2015)... , June 26, 2015 ... the "Vitamin D Market by Analog, Application, End-User & ... report to their offering. This market is projected ... of vitamin D in different applications and rising opportunities in ... China , Italy , and ...
Breaking Medicine Technology:Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3
... today announced the launch of the CELLTRACKS® Circulating Melanoma ... convenient and reliable way to capture CMCs for research ... CMCs, the CELLTRACKS® CMC kit is designed to offer ... based on a specific protein or mutation. ...
... May 24, 2011 TetraLogic Pharmaceuticals, a biopharmaceutical company ... announced that is has closed a $6 million investment ... based oncology focused venture capital fund.  Combined with the ... raised $43 million in the past year. The company ...
Cached Medicine Technology:Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use 2Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use 3TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd. 2TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd. 3TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd. 4
(Date:7/2/2015)... CITY, GA (PRWEB) , ... July 02, 2015 ... ... field sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the socks ... fitness experts and athletic trainers. Their significant popularity has inspired four new, fun ...
(Date:7/2/2015)... ... July 02, 2015 , ... Global leader and compression innovator, ... designed for men. , For style that’s quick on its feet, men will ... is great news for men everywhere because a simple change in socks can dramatically ...
(Date:7/2/2015)... ... , ... Six months ahead of his 80th birthday, Don Stevenson has reached ... for the Pulmonary Hypertension Association (PHA). Stevenson began the walk in Washington State ... mid-September. He left Glasgow, Mont. yesterday morning and is making his way to Wolf ...
(Date:7/2/2015)... , ... July 02, 2015 , ... The ZAC Foundation, ... 2015 swim season with important lessons on how to stay water safe with the ... Couldn’t, Wouldn’t Swim, authored by The ZAC Foundation co-founders, follows Zeke’s water safety journey. ...
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com ... a passion for social fitness. Built to function as a lifestyle community, Active Bunch ... them the opportunity to network, meet, and participate in discussions or group events. ...
Breaking Medicine News(10 mins):Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2
... explain the increased cases , FRIDAY, Nov. 6 (HealthDay News) ... people at higher risk of getting a type of thyroid ... related to cancer, but researchers suspect that the toxic compounds ... also unsure of why thyroid cancer rates are rising around ...
... motor skills later, study suggests, , THURSDAY, Nov. 5 ... at birth often go on to have lifetime disabilities, ... prevent problems. , Now, a new study reports that ... in the babies. , Oxygen starvation at birth ...
... Water has designated the week of November 9, 2009 as ... area as part of a national campaign sponsored by public ... pharmaceutical pollution in our source water supplies. , Sacramento County ... , , Household Hazardous Waste ...
... HeartWare International, Inc. (Nasdaq: HTWR ... less invasive, miniaturized circulatory support technologies revolutionizing the treatment ... scheduled to make presentations at two upcoming investor conferences ... at the Third Annual Canaccord Adams Cardiovascular Conference at ...
... ... procedure that allows almost anyone to sustain life in the first critical minutes ... enough to keep vital organs alive until professional rescuers arrive. AED (Automated External ... get to return to a normal heartbeat. AEDs are very accurate and easy ...
... ... Testing Recommendations Are Expected To Become A Law Very Soon For Commercial ... Apnea Lab Testing Could Cost About $2,000 With A Waiting Period Of ... Not Tolerate Standard CPAP Treatment. Dr. Jin Zhou Of SleepApneaUSA.net Proposed An ...
Cached Medicine News:Health News:Thyroid Cancer Higher in Volcanic Areas 2Health News:California American Water Celebrates 'No Drugs Down the Drain' Week in Sacramento 2Health News:HeartWare to Present at Upcoming Investment Conferences in November 2Health News:A New Era of E-Learning in the Comfort and Convenience of Your Home or Office Without the Classroom Environment 2Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 2Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 3Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 4Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 5
... Narkotron II is a comprehensive vital sign monitor. , ... quality, affordable products for efficiency in patient care., ... 2 - Temp - Multi-gas Sensor (HAL, ... )., ,Optional Functions: ,5-Lead ECG - FiO 2 ...
... monitor is a low-cost, multi-parameter monitor designed ... and surgery. The large display provides bright ... from across the room. The intuitive design ... the monitor in just minutes., ,Standard ...
... the features needed for quality, comprehensive portable ... color display allows you to see up ... ECG. The touch screen allows easy navigation ... gloves or temperature., ,Standard features include ...
... Compact all-in-one anesthesia monitor., ... monitor designed for use in the ... room and PACU. The Cardiocap/5 offers ... the monitoring of oxygenation and circulation ...
Medicine Products: